

Neuragen®

Peripheral Neuropathy Effectiveness Survey Results¹




Background: Health Practitioners with patients suffering with diabetic peripheral neuropathy were invited to participate.² Efficacy was measured primarily by reduction in pain intensity over the first six hours, compared with the pain intensity before the application.

Results: Overall 29 patients satisfactorily completed the survey. Of these, 20 patients (69%) noted some improvement in pain, with 17 patients (59%) noting a remarkable 50-100% improvement, usually within minutes of applying Neuragen topically. This rate of efficacy is comparable or better than the #1 prescribed pharmaceutical for neuropathic pain, Neurontin®, which claims to benefit 50% of patients.

Comments from Study Participants:

- "I am pain free for the first time in ages" - TB 77 year old female with DPN
- "I experienced pain free sleep if applied **Neuragen** after 8pm" – DM 79 year old woman with DPN
- "More effective than any medicine I have used" – NW, 55 year old woman with DPN
- "Helped with chronic pain from neck strain & arthritis as well as my DPN" – MC 64 yr old woman with DPN
- "As good or better than the steroid injections" – LM, 56 year old with degenerative disk pain
- "Improved my sleep and stamina and I am not as depressed as a result" – VC, DPN sufferer
- "Absolutely the best" – FK, 69 yr old male with DPN



Also of note: • Repeated use of **Neuragen** decreased levels of pain for some patients after only one month of use, allowing less medication use less frequently • Many patients reported that **Neuragen** worked better for them than any other medication • Improvement in quality of life was associated with efficacy of **Neuragen**; including sleep, work ability, social life, energy and less depression • Even some of the patients in the 0-25% category reported benefits such as improved joint flexibility, decreased cramping and improved balance. • **Neuragen** was effective for some patients already taking other types of medications but experiencing breakthrough pain

Footnotes:

¹ Study conducted in collaboration with DiabetesinControl.com.

² Patients were required to be over 21 years of age, have a history of painful diabetic peripheral neuropathy of at least three months duration, and an intensity of pain at least moderate at times (ie. inhibits daily activities). Patients may be on medications or nutritional supplements for pain (or other conditions) but must report changes in doses during the time of the survey. Patients were instructed to apply Neuragen™ PN topically to the maximally painful area at least six times in one month, and complete one patient diary for each application. Secondary efficacy parameters included: changes in response over the month of repeated measurement, improvement in quality of life parameters, reduction in use of other analgesics, and an overall assessment made by the patient at the end of the month period. These parameters were collected in an exit interview conducted by the practitioner at the end of the month period.